Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma

References

• Han ZG. 2012; Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet. 13:171–205. doi:10.1146/annurev-genom-090711-163752.
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1.
   PubMed Web of Science ®Google Scholar
• Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep. 2010;12(3):186–192. doi:10.1007/s11912-010-0094-3.
   PubMed Web of Science ®Google Scholar
• Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642–654. doi:10.1016/j.jhep.2012.03.035.
   PubMed Web of Science ®Google Scholar
• Davis BK, Wen H, Ting JP. 2011; The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 29:707–735. doi:10.1146/annurev-immunol-031210-101405.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2010;285(9):6477–6488. doi:10.1074/jbc.M109.064907.
   PubMed Web of Science ®Google Scholar
• Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SPS, Geller DA, Lotze MT, Tsung A. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012;55(6):1863–1875. doi:10.1002/hep.25572.
   PubMed Web of Science ®Google Scholar
• Celardo I, Grespi F, Antonov A, Bernassola F, Garabadgiu AV, Melino G, Amelio I. 2013; Caspase-1 is a novel target of p63 in tumor suppression. Cell Death Dis. 4:e645. doi:10.1038/cddis.2013.175.
   PubMed Web of Science ®Google Scholar
• Chu Q, Jiang Y, Zhang W, Xu C, Du W, Tuguzbaeva G, Qin Y, Li A, Zhang L, Sun G, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget. 2016;7(51):84658–84665. doi:10.18632/oncotarget.12384.
   PubMedGoogle Scholar
• Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC, Flavell RA. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010;107(50):21635–21640. doi:10.1073/pnas.1016814108.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–759. doi:10.1038/nri1703.
   PubMed Web of Science ®Google Scholar
• Liu J, Tao X, Zhang J, Wang P, Sha M, Ma Y, Geng X, Feng L, Shen Y, Yu Y, et al. Small ubiquitin-related modifier 1 is involved in hepatocellular carcinoma progression via mediating p65 nuclear translocation. Oncotarget. 2016;7(16):22206–22218. doi:10.18632/oncotarget.8066.
   PubMedGoogle Scholar
• Liu LP, Ho RLK, Chen GG, Lai PBS. Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res. 2012;18(20):5662–5671. doi:10.1158/1078-0432.CCR-12-0552.
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-1377.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109. doi:10.1158/0008-5472.CAN-04-1443.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, De Oliveira AC, Santoro A, Raoul J-L, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin W-C, Chiang I-T, Chang Y-F, Chen C-W, Su S-H, Chen C-L, Hwang -J-J. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo. Biomed Pharmacother. 2012;66(1):12–20. doi:10.1016/j.biopha.2011.09.011.
   PubMed Web of Science ®Google Scholar
• Jing YY, Han Z-P, Sun K, Zhang -S-S, Hou J, Liu Y, Li R, Gao L, Zhao X, Zhao Q-D, et al. 2012; Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 10:98. doi:10.1186/1741-7015-10-98.
   PubMed Web of Science ®Google Scholar
• Lai FB, Liu W-T, Jing -Y-Y, Yu G-F, Han Z-P, Yang X, Zeng J-X, Zhang H-J, Shi R-Y, Li X-Y, et al. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-kappaB/HIF-1alpha pathway. Cancer Lett. 2016;378(2):131–141. doi:10.1016/j.canlet.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33. doi:10.1007/s10555-008-9169-0.
   PubMed Web of Science ®Google Scholar
• Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology. 2010;52(3):945–953. doi:10.1002/hep.23748.
   PubMed Web of Science ®Google Scholar
• Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010;29(2):285–293. doi:10.1007/s10555-010-9224-5.
   PubMed Web of Science ®Google Scholar
• Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43(3):374–379. doi:10.1016/j.cyto.2008.07.014.
   PubMed Web of Science ®Google Scholar
• Liu J, Hildebrandt T, Knetzger S-M, Schrauder MG, Jud SM, Hein A, Rauh C, Fasching PA, Beckmann MW, Thiel FC. 2015; Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma. BMC Cancer. 15:675. doi:10.1186/s12885-015-1584-3.
   PubMed Web of Science ®Google Scholar
• Llovet, JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• Liu W-T, Jing -Y-Y, Yu G-F, Han Z-P, Yu -D-D, Fan Q-M, Ye F, Li R, Gao L, Zhao Q-D, et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett. 2015;358(2):136–143. doi:10.1016/j.canlet.2014.12.019.
   PubMed Web of Science ®Google Scholar
• Sepehri Z, Kiani Z, Kohan F, Alavian SM, Ghavami S. 2017; Toll like receptor 4 and hepatocellular carcinoma; A systematic review. Life Sci. 179:80–87. doi:10.1016/j.lfs.2017.04.025.
   PubMed Web of Science ®Google Scholar
• Lin A, Wang G, Zhao H, Zhang Y, Han Q, Zhang C, Tian Z, Zhang J. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology. 2016;5(2):e1074376. doi:10.1080/2162402X.2015.1074376.
   PubMed Web of Science ®Google Scholar
• Yang J, Li M, Zheng QC. 2015; Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2:11–17. doi:10.2147/JHC.S44515.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yan J, Lin H, Hua F, Wang X, Liu H, Lv X, Yu J, Mi S, Wang J, et al. Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatology. 2013;57(5):1869–1881. doi:10.1002/hep.26234.
   PubMed Web of Science ®Google Scholar